Ardelyx earnings date
Ardelyx (41X) Q3 2026 Earnings Report
CH:41X Q3 2026 EPS Results
- Actual EPS
- CHF 0.00
- Consensus EPS
- -CHF 0.01
- Beat/Miss
- Beat by +CHF 0.01
- One Year Ago EPS
- CHF 0.00
CH:41X Q3 2026 Revenue Results
- Actual Revenue
- CHF 105.37M
- Expected Revenue
- CHF 105.65M
- Beat/Miss
- Missed by -CHF 276.52K
- YoY Revenue Growth
- +15.70%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/03/2026
- Time
- After Close
- Conference Call
- Tuesday, November 3, 2026
Ardelyx's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was predominantly positive, supported by 19% total product revenue growth, 23% IBSRELA growth, strong demand trends, reaffirmed 2026 guidance, improved net loss, $285.3 million of liquidity, and ahead-of-schedule enrollment in the ACCEL Phase III trial. The main challenges were persistent payer friction, complex XPHOZAH reimbursement dynamics, gross-to-net erosion, recent prescription-data volatility, and continued operating investments. Management remained confident in execution and the path to profitability in 2027.
Ardelyx reaffirmed full year 2026 IBSRELA guidance of $350 million to $370 million, representing annual growth of more than 30% at the midpoint, and full year 2026 XPHOZAH revenue guidance of $110 million to $120 million; full year 2026 operating expenses are expected to be below $500 million, with profitability expected to occur in 2027, supported by a greater than 95% gross profit margin, while the company’s long-term view is achieving $1 billion in annual revenue for IBSRELA and it expects to report ACCEL top line results in the second half of 2027.
- Total Product Revenue GrowthThird-quarter product revenue was $125.5 million, compared with $105.5 million in the same period last year, representing 19% year-over-year growth. IBSRELA and XPHOZAH generated over $125 million in combined revenue.
- Strong IBSRELA Revenue and DemandIBSRELA revenue was $96.3 million in Q3, up 23% year-over-year. Total writers, total prescriptions, and market share continued to grow, with demand reaching all-time highs. Management reaffirmed its long-term view of achieving $1 billion in annual revenue.
- IBSRELA Access Initiatives Gaining ProgressThe company reported progress in reducing payer friction. It expanded its sales force, doubled its field reimbursement team, and continued efforts to transition writers to the IBSRELA pharmacy network. When the network is utilized, patients experience 2 to 3 times higher fulfillment rates, faster fill times, and at least one additional refill per patient annually.
- IBSRELA Direct-to-Consumer CampaignArdelyx launched its first IBSRELA direct-to-consumer advertisement on September 1, intended to reach more than 10 million people through Netflix, Hulu, Prime Video, Disney, and other outlets. In testing with IBS-C patients, 91% said they would ask their doctor whether IBSRELA was right for them, and the campaign has driven increased traffic to the consumer-focused website.
- IBS-C Market Opportunity and Real-World EvidenceManagement cited more than 7 million prescriptions annually for IBS-C-approved medications and said more than 70% of patients continue to experience persistent symptoms. Real-world data presented at the American College of Gastroenterology meeting showed that GI-related health care resource utilization drops for patients on IBSRELA, primarily due to fewer doctor visits and labs.
- XPHOZAH Revenue and Paid Prescription GrowthXPHOZAH revenue was $29.2 million in Q3, up 7% year-over-year. Paid prescriptions increased 22% compared with the same quarter in 2025, and management said the need for the product remains high among dialysis patients with hyperphosphatemia.
- XPHOZAH Clinical EvidenceAt American Society of Nephrology Kidney Week, Ardelyx presented real-world evidence supporting XPHOZAH's ability to consistently reduce serum phosphate, along with data highlighting the difficulty of managing hyperphosphatemia and the morbidity and mortality associated with cumulative phosphate burden.
- ACCEL Phase III Trial Fully EnrolledThe ACCEL Phase III trial evaluating IBSRELA in chronic idiopathic constipation was fully enrolled ahead of schedule. Management said the enrollment pace reflected physician enthusiasm for a new treatment option and expects to report top-line results in the second half of 2027.
- Pipeline Expansion and CIC RationaleTenapanor remains the foundation of the pipeline. Management said patients with chronic idiopathic constipation and IBS-C have overlapping symptoms, that the CIC market is significantly larger than the IBS-C market, and that the ACCEL trial has been well received by physicians.
- Improved Net Loss and Strong LiquidityThird-quarter net loss narrowed to $700,000 from $1.0 million in Q3 2025. Ardelyx ended the quarter with $285.3 million in cash, cash equivalents, and short-term investments, with revenue funding operations and the pipeline.
- Reaffirmed 2026 GuidanceThe company reaffirmed 2026 IBSRELA revenue guidance of $350 million to $370 million, representing annual growth of more than 30% at the midpoint. XPHOZAH revenue guidance remained $110 million to $120 million, and full-year operating expenses are expected to be below $500 million.
- Path to Profitability and Gross MarginManagement continues to expect profitability in 2027. The company reported a greater than 95% gross profit margin and said that prudently managed operating expenses should support operating-margin growth.
CH:41X Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | 0.03- | 0 | ― | ― |
| Nov 03, 2026 | 2026 (Q3) | -0.010.00 | 0 | ― | |
| Aug 06, 2026 | 2026 (Q2) | -0.05-0.06 | -0.07 | 12.50% (+0.01) | |
| Apr 30, 2026 | 2026 (Q1) | -0.12-0.12 | -0.14 | 11.76% (+0.02) | |
| Feb 19, 2026 | 2025 (Q4) | 0.010.00 | 0.02 | -100.00% (-0.02) | |
| Oct 30, 2025 | 2025 (Q3) | -0.050.00 | 0 | ― | |
| Aug 04, 2025 | 2025 (Q2) | -0.11-0.07 | -0.06 | -14.29% (-0.01) | |
| May 01, 2025 | 2025 (Q1) | -0.09-0.14 | -0.09 | -54.55% (-0.05) | |
| Feb 20, 2025 | 2024 (Q4) | 0.000.02 | -0.1 | 116.67% (+0.12) | |
| Oct 31, 2024 | 2024 (Q3) | -0.040.00 | 0.02 | -100.00% (-0.02) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
